Related Experiment Videos
Immunosuppressive activity of cyclolinopeptide A
Z Wieczorek1, B Bengtsson, J Trojnar
1Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
Summary
Cyclolinopeptide A (CLA), a natural peptide from linseed oil, demonstrates potent immunosuppressive activity comparable to cyclosporin A (CS-A). This peptide shows promise for medical applications due to its efficacy and lack of toxicity in animal studies.
Area of Science:
- Immunology
- Pharmacology
- Natural Products Chemistry
Background:
- Cyclolinopeptide A (CLA) is a cyclic nonapeptide isolated from linseed oil.
- CLA exhibits immunosuppressive properties comparable to cyclosporin A (CS-A).
Purpose of the Study:
- To evaluate the immunosuppressive effects of CLA on humoral and cellular immune responses.
- To investigate the mechanism of action of CLA, including its effect on Interleukin-1 and Interleukin-2.
- To assess the safety and toxicity profile of CLA in preclinical models.
Main Methods:
- Plaque-forming cell assays (in vitro and in vivo) to assess humoral immunity.
- Delayed-type hypersensitivity tests, skin-allograft rejection, and graft-vs.-host reaction assays for cellular immunity.
- In vitro lymphocyte proliferation assays and autologous rosette-forming cell tests to elucidate mechanism of action.
Main Results:
- CLA significantly suppressed primary and secondary humoral immune responses.
- CLA inhibited cellular immune responses, including delayed-type hypersensitivity, skin-allograft rejection, and graft-vs.-host reactions.
- CLA demonstrated comparable efficacy to CS-A in all tested immunological assays and inhibited Interleukin-1 and Interleukin-2 activity.
Conclusions:
- Cyclolinopeptide A possesses potent immunosuppressive activity, similar to cyclosporin A.
- CLA effectively modulates both humoral and cellular immunity.
- CLA exhibits a favorable safety profile, with no observed toxic effects in preclinical studies, suggesting significant therapeutic potential in medicine.